Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Isosorbide Dinitrate tablets USP (US RLD — Isordil tablet) in the strengths of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. The drug is used to prevent attacks of chest pain (angina). It dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump. It will be manufactured at the group's formulations manufacturing facility at Baddi.
The group also received the final approval for Desonide Cream (US RLD — Desonide Cream), 0.05%. The drug is a mild corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash) to reduce swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
The group now has 278 approvals and has so far filed over 330 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Powered by Capital Market - Live News